Peripheral T-Cell Lymphoma - Competitive Landscape, Market Insights, Epidemiology and Market Forecast-2023
This report can be delivered to the clients within 24 Hours
DelveInsight’s ‘Peripheral T-Cell Lymphoma (PTCL) - Competitive Landscape, Market Insights, Epidemiology and Market Forecast-2025’ report provides provides the comprehensive insights on the competitive landscape and market of Peripheral T-Cell Lymphoma (PTCL).
The report covers an overview of the Peripheral T-Cell Lymphoma along with the epidemiology and the market scenario in the 7MM – United States, EU5 (Germany, France, Spain Italy, United Kingdom) and Japan. The Report provides a comprehensive review of the unmet medical needs of the disease, market trends, drivers and market barriers.
The competitive landscape of the report covers both pipeline and marketed portfolio of the indication. Cutaneous Squamous Cell Carcinoma pipeline provides information on the therapeutic drugs in development and comparative analysis at various stages covering clinical and pre-clinical & discovery stages, therapeutics assessment by Monotherapy/Combination products and Molecule Type drug analysis. It also provides in-depth analysis on the Phase III profile covering clinical trial studies, recent developments and SWOT Analysis.
The Report covers detailed historical and forecasted epidemiology of Peripheral T-Cell Lymphoma(CTCL) in the 7MM (till 2025), segmented on the basis of sub-types (Anaplastic T Cell Lymphoma, AngioImmunoblastic T Cell Lymphoma, NK/T Cell Lymphoma and others), as well as stages of the disease. According to DelveInsight, the incident cases of Peripheral T-Cell Lymphoma are expected to reach up to 24,630 by the end of 2025 at a CAGR of XX% from 2013 to 2025. High incident cases were observed in the United States as compared to EU5 and Japan.
The Report covers the therapeutics market revenue, treatment practice/algorithm and detailed market size forecast of Peripheral T-Cell Lymphoma from 2017 to 2025 segmented by seven major markets. United States contributes the major share of Peripheral T-Cell Lymphoma market as compared to EU5 countries and Japan.
Market is mainly driven by Beleodaq (Spectrum Pharmaceuticals, Inc.), Istodax (Celgene Corporation), Poteligeo (Kyowa Hakko Kirin Co., Ltd. and Folotyn (Spectrum Pharmaceuticals) being approved for the treatment of Peripheral T-Cell Lymphoma.
The therapeutic market of Peripheral T-Cell Lymphoma in 7MM is expected to reach USD XXX Million in 2025 at the CAGR of 8.3% for the forecasted period i.e., 2013-2025.
KEY COVERAGE AND BENEFITS:
DelveInsight’s ‘Peripheral T-Cell Lymphoma (PTCL) - Competitive Landscape, Market Insights, Epidemiology and Market Forecast-2025’ report provides provides the comprehensive insights on the competitive landscape and market of Peripheral T-Cell Lymphoma (PTCL).
The report covers an overview of the Peripheral T-Cell Lymphoma along with the epidemiology and the market scenario in the 7MM – United States, EU5 (Germany, France, Spain Italy, United Kingdom) and Japan. The Report provides a comprehensive review of the unmet medical needs of the disease, market trends, drivers and market barriers.
The competitive landscape of the report covers both pipeline and marketed portfolio of the indication. Cutaneous Squamous Cell Carcinoma pipeline provides information on the therapeutic drugs in development and comparative analysis at various stages covering clinical and pre-clinical & discovery stages, therapeutics assessment by Monotherapy/Combination products and Molecule Type drug analysis. It also provides in-depth analysis on the Phase III profile covering clinical trial studies, recent developments and SWOT Analysis.
The Report covers detailed historical and forecasted epidemiology of Peripheral T-Cell Lymphoma(CTCL) in the 7MM (till 2025), segmented on the basis of sub-types (Anaplastic T Cell Lymphoma, AngioImmunoblastic T Cell Lymphoma, NK/T Cell Lymphoma and others), as well as stages of the disease. According to DelveInsight, the incident cases of Peripheral T-Cell Lymphoma are expected to reach up to 24,630 by the end of 2025 at a CAGR of XX% from 2013 to 2025. High incident cases were observed in the United States as compared to EU5 and Japan.
The Report covers the therapeutics market revenue, treatment practice/algorithm and detailed market size forecast of Peripheral T-Cell Lymphoma from 2017 to 2025 segmented by seven major markets. United States contributes the major share of Peripheral T-Cell Lymphoma market as compared to EU5 countries and Japan.
Market is mainly driven by Beleodaq (Spectrum Pharmaceuticals, Inc.), Istodax (Celgene Corporation), Poteligeo (Kyowa Hakko Kirin Co., Ltd. and Folotyn (Spectrum Pharmaceuticals) being approved for the treatment of Peripheral T-Cell Lymphoma.
The therapeutic market of Peripheral T-Cell Lymphoma in 7MM is expected to reach USD XXX Million in 2025 at the CAGR of 8.3% for the forecasted period i.e., 2013-2025.
KEY COVERAGE AND BENEFITS:
- The report will help in developing business strategies by understanding the trends shaping and driving the global Peripheral T-Cell Lymphoma market.
- Overview of the Global pipeline scenario for global Peripheral T-Cell Lymphoma, products and associated companies information
- Pipeline analysis across different phases, emerging trends and comparative analysis of pipeline products with detailed clinical profiles, mechanism of action, route of administration and molecule type, along with product development activities
- Organize sales and marketing efforts by identifying the best opportunities for Peripheral T-Cell Lymphoma in US, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.
- The report provides historical as well as forecasted epidemiology of Peripheral T-Cell Lymphoma in the 7MM covering United States, EU5 (Germany, Spain, Italy, France and United Kingdom) and Japan from 2013-2025.
- To understand the future market competition in the global Peripheral T-Cell Lymphoma market and Insightful review of the key market drivers and barriers.
- To understand the regulatory scenario in major markets.
- The Report also covers the detailed global historical and forecasted Peripheral T-Cell Lymphoma market covering United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan from 2013-2025.
Report Introduction
Peripheral T-Cell Lymphoma (PTCL) Market Overview at a Glance
Global Market Size of PTCL in 2016
Global Market Size of PTCL in 2025
Overview
Subtypes of Peripheral T cell lymphoma
Nodal Peripheral T cell lymphomas
Extranodal Peripheral T Cell Lymphomas
Cutaneous- Peripheral T Cell Lymphomas
Leukemic- Peripheral T Cell Lymphomas
Pathophysiology
Staging
Diagnosis
Peripheral T-Cell Lymphoma (PTCL) Geography wise Incident Cases
7MM Incident PTCL Cases in 2016
7MM Incident PTCL Cases in 2025
Epidemiology and Patient Population
Key Points
United States
Assumptions and Rationale
Incident Cases of PTCL in United States
Stage wise PTCL Cases in United States
Common Types of PTCL in United States
Europe
Assumptions and Rationale
Germany
Incident Cases of PTCL in Germany
Stage wise PTCL Cases in Germany
Common Types of PTCL Cases in Germany
Italy
Incident Cases of PTCL in Italy
Stage wise PTCL Cases in Italy
Common Types of PTCL Cases in Italy
Spain
Incident Cases of PTCL in Spain
Stage wise PTCL Cases in Spain
Common Types of PTCL Cases in Spain
France
Incident Cases of PTCL in France
Stage wise PTCL Cases in France
Common Types of PTCL Cases in France
United Kingdom
Incident Cases of PTCL in United Kingdom
Stage wise PTCL Cases in United Kingdom
Common Types of PTCL Cases in United Kingdom
Japan
Assumptions and Rationale
Incident Cases of PTCL in Japan
Stage wise PTCL Cases in Japan
Common Types of PTCL Cases in Japan
Treatment Algorithm
United States
Europe
Unmet Needs
Marketed Drugs
Beleodaq (Belinostat): Onxeo S.A.
Drug Description
Mechanism of Action
Advantages & Disadvantages
Safety and Efficacy of Beleodaq
Product Profile
Istodax (Romidepsin): Celgene Corporation
Drug Description
Mechanism of Action
Advantages & Disadvantages
Safety and Efficacy of Istodax
Product Profile
Folotyn (Pralatrexate): Spectrum Pharmaceuticals
Drug Description
Mechanism of Action
Advantages & Disadvantages
Safety and Efficacy of Folotyn
Product Profile
Poteligeo (Mogamulizumab): Kyowa Hakko Kirin Co, Ltd.
Drug Description
Mechanism of Action
Advantages & Disadvantages
Safety and Efficacy of Poteligeo
Product Profile
Adcetris (Brentuximab vedotin): Seattle Genetics
Drug Description
Mechanism of Action
Advantages & Disadvantages
Safety and Efficacy of Adcetris
Product Profile
Rituxan (MabThera): Genentech
Drug Description
Mechanism of Action
Advantages & Disadvantages
Safety and Efficacy of Rituxan
Product Profile
Emerging Therapies
Phase III
Brentuximab vedotin: Seattle Genetics
Advantages & Disadvantages
Product Profile
Clinical Development
Clinical Pipeline Activity
Ongoing Trials Information
Clinical Trial by Phase
Masitinib: AB Science SA
Advantages & Disadvantages
Product Profile
Clinical Development
Clinical Pipeline Activity
Ongoing Trials Information
Clinical Trial by Phase
Phase II
Darinaparsin: Solasia Pharma
Advantages & Disadvantages
Product Profile
Clinical Development
Clinical Pipeline Activity
Ongoing Trials Information
Clinical Trial by Phase
Fenretinide: CerRx, Inc
Advantages & Disadvantages
Product Profile
Clinical Development
Clinical Pipeline Activity
Ongoing Trials Information
Clinical Trial by Phase
Denileukin diftitox: Eisai Co Ltd
Advantages & Disadvantages
Product Profile
Clinical Development
Clinical Pipeline Activity
Ongoing Trials Information
Clinical Trial by Phase
Lenalidomide: Celgene Corporation
Advantages & Disadvantages
Product Profile
Clinical Development
Clinical Pipeline Activity
Ongoing Trials Information
Clinical Trial by Phase
Market Size
Global PTCL Market Analysis
Overview of Global PTCL Market (2013-2025)
Total 7MM PTCL Market Analysis
Overview of Total PTCL Market (2013-2025)
PTCL Region wise Market Analysis
Region wise Market Size (2016)
Region wise Market Size (2025)
7MM PTCL: Country-Wise Market Analysis
Overview on Total PTCL Market (2016)
Overview on Total PTCL Market (2025)
Global PTCL: Market Analysis
United States Market Size
Europe Market Size
Germany Market Size
France Market Size
United Kingdom Market Size
Spain Market Size
Italy Market Size
Japan Market Size
Market Drivers
Market Barriers
Appendix
Report Methodology
Consulting Services
Disclaimer
About DelveInsight
Peripheral T-Cell Lymphoma (PTCL) Market Overview at a Glance
Global Market Size of PTCL in 2016
Global Market Size of PTCL in 2025
Overview
Subtypes of Peripheral T cell lymphoma
Nodal Peripheral T cell lymphomas
Extranodal Peripheral T Cell Lymphomas
Cutaneous- Peripheral T Cell Lymphomas
Leukemic- Peripheral T Cell Lymphomas
Pathophysiology
Staging
Diagnosis
Peripheral T-Cell Lymphoma (PTCL) Geography wise Incident Cases
7MM Incident PTCL Cases in 2016
7MM Incident PTCL Cases in 2025
Epidemiology and Patient Population
Key Points
United States
Assumptions and Rationale
Incident Cases of PTCL in United States
Stage wise PTCL Cases in United States
Common Types of PTCL in United States
Europe
Assumptions and Rationale
Germany
Incident Cases of PTCL in Germany
Stage wise PTCL Cases in Germany
Common Types of PTCL Cases in Germany
Italy
Incident Cases of PTCL in Italy
Stage wise PTCL Cases in Italy
Common Types of PTCL Cases in Italy
Spain
Incident Cases of PTCL in Spain
Stage wise PTCL Cases in Spain
Common Types of PTCL Cases in Spain
France
Incident Cases of PTCL in France
Stage wise PTCL Cases in France
Common Types of PTCL Cases in France
United Kingdom
Incident Cases of PTCL in United Kingdom
Stage wise PTCL Cases in United Kingdom
Common Types of PTCL Cases in United Kingdom
Japan
Assumptions and Rationale
Incident Cases of PTCL in Japan
Stage wise PTCL Cases in Japan
Common Types of PTCL Cases in Japan
Treatment Algorithm
United States
Europe
Unmet Needs
Marketed Drugs
Beleodaq (Belinostat): Onxeo S.A.
Drug Description
Mechanism of Action
Advantages & Disadvantages
Safety and Efficacy of Beleodaq
Product Profile
Istodax (Romidepsin): Celgene Corporation
Drug Description
Mechanism of Action
Advantages & Disadvantages
Safety and Efficacy of Istodax
Product Profile
Folotyn (Pralatrexate): Spectrum Pharmaceuticals
Drug Description
Mechanism of Action
Advantages & Disadvantages
Safety and Efficacy of Folotyn
Product Profile
Poteligeo (Mogamulizumab): Kyowa Hakko Kirin Co, Ltd.
Drug Description
Mechanism of Action
Advantages & Disadvantages
Safety and Efficacy of Poteligeo
Product Profile
Adcetris (Brentuximab vedotin): Seattle Genetics
Drug Description
Mechanism of Action
Advantages & Disadvantages
Safety and Efficacy of Adcetris
Product Profile
Rituxan (MabThera): Genentech
Drug Description
Mechanism of Action
Advantages & Disadvantages
Safety and Efficacy of Rituxan
Product Profile
Emerging Therapies
Phase III
Brentuximab vedotin: Seattle Genetics
Advantages & Disadvantages
Product Profile
Clinical Development
Clinical Pipeline Activity
Ongoing Trials Information
Clinical Trial by Phase
Masitinib: AB Science SA
Advantages & Disadvantages
Product Profile
Clinical Development
Clinical Pipeline Activity
Ongoing Trials Information
Clinical Trial by Phase
Phase II
Darinaparsin: Solasia Pharma
Advantages & Disadvantages
Product Profile
Clinical Development
Clinical Pipeline Activity
Ongoing Trials Information
Clinical Trial by Phase
Fenretinide: CerRx, Inc
Advantages & Disadvantages
Product Profile
Clinical Development
Clinical Pipeline Activity
Ongoing Trials Information
Clinical Trial by Phase
Denileukin diftitox: Eisai Co Ltd
Advantages & Disadvantages
Product Profile
Clinical Development
Clinical Pipeline Activity
Ongoing Trials Information
Clinical Trial by Phase
Lenalidomide: Celgene Corporation
Advantages & Disadvantages
Product Profile
Clinical Development
Clinical Pipeline Activity
Ongoing Trials Information
Clinical Trial by Phase
Market Size
Global PTCL Market Analysis
Overview of Global PTCL Market (2013-2025)
Total 7MM PTCL Market Analysis
Overview of Total PTCL Market (2013-2025)
PTCL Region wise Market Analysis
Region wise Market Size (2016)
Region wise Market Size (2025)
7MM PTCL: Country-Wise Market Analysis
Overview on Total PTCL Market (2016)
Overview on Total PTCL Market (2025)
Global PTCL: Market Analysis
United States Market Size
Europe Market Size
Germany Market Size
France Market Size
United Kingdom Market Size
Spain Market Size
Italy Market Size
Japan Market Size
Market Drivers
Market Barriers
Appendix
Report Methodology
Consulting Services
Disclaimer
About DelveInsight
LIST OF TABLES
Table 1: Incident Cases of PTCL in United States (2013-2025)
Table 2: Stage wise number of cases in United States (2016)
Table 3: Common Types of cases in United States (2016)
Table 4: Incident Cases of PTCL in Germany (2013-2025)
Table 5: Stage wise number of cases in Germany (2016)
Table 6: Common Types of cases in Germany (2016)
Table 7: Incident Cases of PTCL in Italy (2013-2025)
Table 8: Stage wise number of cases in Italy (2016)
Table 9: Common Types of cases in Italy (2016)
Table 10: Incident Cases of PTCL in Spain (2013-2025)
Table 11: Stage wise number of cases in Spain (2016)
Table 12: Common Types of cases in Spain (2016)
Table 13: Incident Cases of PTCL in France (2013-2025)
Table 14: Stage wise number of cases in France (2016)
Table 15: Common Types of cases in France (2016)
Table 16: Incident Cases of PTCL in United Kingdom (2013-2025)
Table 17: Stage wise number of cases in United Kingdom (2016)
Table 18: Common Types of cases in United Kingdom (2016)
Table 19: Incident Cases of PTCL in Japan (2013-2025)
Table 20: Stage wise number of cases in Japan (2016)
Table 21: Common Types of cases in Japan (2016)
Table 22: List of Marketed Drugs for Peripheral T Cell Lymphoma
Table 23: List of Emerging therapies for Peripheral T- Cell Lymphoma
Table 24: Brentuximab Vedotin, Clinical Trials by Zone, 2017
Table 25: Clinical Trials by Trial status, 2017
Table 26: Masitinib, Clinical Trials by Zone, 2017
Table 27: Clinical Trials by Trial status, 2017
Table 28: Darinaparsin, Clinical Trials by Zone, 2017
Table 29: Clinical Trials by Trial status, 2017
Table 30:Fenretinide, Clinical Trials by Zone, 2017
Table 31: Clinical Trials by Trial status, 2017
Table 32: Denileukin diftitox, Clinical Trials by Zone, 2017
Table 33: Clinical Trials by Trial status, 2017
Table 34: Lenalidomide, Clinical Trials by Zone, 2017
Table 35: Clinical Trials by Trial status, 2017
Table 36: Global Market Size of PTCL in USD Million, (2013-2025)
Table 37: Market Size of PTCL-7MM in USD Million (2013-2025)
Table 38: Total PTCL, Market Revenue (2016) as per the 7MM
Table 39: Total PTCL, Market Revenue (2025) as per the 7MM
Table 40: Market Size of PTCL-United States in USD Million (2013-2025)
Table 41: Market Size of PTCL-Germany in USD Million (2013-2025)
Table 42: Market Size of PTCL-France in USD Million (2013-2025)
Table 43: Market Size of PTCL-United Kingdom in USD Million (2013-2025)
Table 44: Market Size of PTCL-Spain in USD Million (2013-2025)
Table 45: Market Size of PTCL-Italy in USD Million (2013-2025)
Table 46: Market Size of PTCL-Japan in USD Million (2013-2025)
Table 1: Incident Cases of PTCL in United States (2013-2025)
Table 2: Stage wise number of cases in United States (2016)
Table 3: Common Types of cases in United States (2016)
Table 4: Incident Cases of PTCL in Germany (2013-2025)
Table 5: Stage wise number of cases in Germany (2016)
Table 6: Common Types of cases in Germany (2016)
Table 7: Incident Cases of PTCL in Italy (2013-2025)
Table 8: Stage wise number of cases in Italy (2016)
Table 9: Common Types of cases in Italy (2016)
Table 10: Incident Cases of PTCL in Spain (2013-2025)
Table 11: Stage wise number of cases in Spain (2016)
Table 12: Common Types of cases in Spain (2016)
Table 13: Incident Cases of PTCL in France (2013-2025)
Table 14: Stage wise number of cases in France (2016)
Table 15: Common Types of cases in France (2016)
Table 16: Incident Cases of PTCL in United Kingdom (2013-2025)
Table 17: Stage wise number of cases in United Kingdom (2016)
Table 18: Common Types of cases in United Kingdom (2016)
Table 19: Incident Cases of PTCL in Japan (2013-2025)
Table 20: Stage wise number of cases in Japan (2016)
Table 21: Common Types of cases in Japan (2016)
Table 22: List of Marketed Drugs for Peripheral T Cell Lymphoma
Table 23: List of Emerging therapies for Peripheral T- Cell Lymphoma
Table 24: Brentuximab Vedotin, Clinical Trials by Zone, 2017
Table 25: Clinical Trials by Trial status, 2017
Table 26: Masitinib, Clinical Trials by Zone, 2017
Table 27: Clinical Trials by Trial status, 2017
Table 28: Darinaparsin, Clinical Trials by Zone, 2017
Table 29: Clinical Trials by Trial status, 2017
Table 30:Fenretinide, Clinical Trials by Zone, 2017
Table 31: Clinical Trials by Trial status, 2017
Table 32: Denileukin diftitox, Clinical Trials by Zone, 2017
Table 33: Clinical Trials by Trial status, 2017
Table 34: Lenalidomide, Clinical Trials by Zone, 2017
Table 35: Clinical Trials by Trial status, 2017
Table 36: Global Market Size of PTCL in USD Million, (2013-2025)
Table 37: Market Size of PTCL-7MM in USD Million (2013-2025)
Table 38: Total PTCL, Market Revenue (2016) as per the 7MM
Table 39: Total PTCL, Market Revenue (2025) as per the 7MM
Table 40: Market Size of PTCL-United States in USD Million (2013-2025)
Table 41: Market Size of PTCL-Germany in USD Million (2013-2025)
Table 42: Market Size of PTCL-France in USD Million (2013-2025)
Table 43: Market Size of PTCL-United Kingdom in USD Million (2013-2025)
Table 44: Market Size of PTCL-Spain in USD Million (2013-2025)
Table 45: Market Size of PTCL-Italy in USD Million (2013-2025)
Table 46: Market Size of PTCL-Japan in USD Million (2013-2025)
LIST OF FIGURES
Figure 1: Classification of Peripheral T- Cell Lymphoma
Figure 2: T-cell neoplasms: organ of origin or involvement and associated chromosomal and genetic alterations.
Figure 3: Incident Cases of PTCL in United States (2013-2025)
Figure 4: Stage wise PTCL cases in United States (2013-2025)
Figure 5: Common types of PTCL in United States (2013-2025)
Figure 6: Incident Cases of PTCL in Germany (2013-2025)
Figure 7: Stage wise PTCL cases in Germany (2013-2025)
Figure 8: Common types of PTCL in Germany (2013-2025)
Figure 9: Incident Cases of PTCL in Italy (2013-2025)
Figure 10: Stage wise PTCL cases in Italy (2013-2025)
Figure 11: Common types of PTCL in Italy (2013-2025)
Figure 12: Incident Cases of PTCL in Spain (2013-2025)
Figure 13: Stage wise PTCL cases in Spain (2013-2025)
Figure 14: Common types of PTCL in Spain (2013-2025)
Figure 15: Incident Cases of PTCL in France (2013-2025)
Figure 16: Stage wise PTCL cases in France (2013-2025)
Figure 17: Common types of PTCL in France (2013-2025)
Figure 18: Incident Cases of PTCL in United Kingdom (2013-2025)
Figure 19: Stage wise PTCL in United Kingdom (2013-2025)
Figure 20: Common types of PTCL in United Kingdom (2013-2025)
Figure 21: Incident Cases of PTCL in Japan (2013-2025)
Figure 22: Stage wise PTCL cases in Japan (2013-2025)
Figure 23: Common Types of PTCL in Japan (2013-2025)
Figure 24: First Line of therapy for PTCL -NOS
Figure 25: Second Line of therapy for PTCL –NOS with Stem cell transplant
Figure 26: First Line of therapy for ALCL, ALK+
Figure 27: Second Line of therapy for ALCL- ALK+ with Stem cell transplant
Figure 28: First Line of therapy for ALCL, ALK-
Figure 29: Second Line of therapy for ALCL- ALK- with Stem cell transplant
Figure 30: First Line of therapy for AICL
Figure 31: Second Line of therapy for AICL with Stem cell transplant
Figure 32: First Line of therapy for Enteropathy associated TCL
Figure 33: Second Line of therapy for enetropathy associated T cell lymphoma with stem cell transplantation
Figure 34: Treatment for Nodal and Extranodal Peripheral T cell Lymphomas
Figure 35: Treatment for relapsed/ refractory Nodal and Extranodal Peripheral T cell Lymphomas
Figure 36: Brentuximab vedotin, Clinical Trials by Zone (%), 2017
Figure 37: Brentuximab Vedotin, Clinical Trials by Trial status (%), 2017
Figure 38: Masitinib, Clinical Trials by Zone (%), 2017
Figure 39: Masatinib, Clinical Trials by Trial status (%), 2017
Figure 40: Darinaparsin, Clinical Trials by Zone (%), 2017
Figure 41: Darinaparsin, Clinical Trials by Trial status (%), 2017
Figure 42: Fenretinide, Clinical Trials by Zone (%), 2017
Figure 43: Fenretinide, Clinical Trials by Trial status (%), 2017
Figure 44: Denileukin diftitox, Clinical Trials by Zone (%), 2017
Figure 45: Denileukin diftitox, Clinical Trials by Trial status (%), 2017
Figure 46: Lenalidomide, Clinical Trials by Zone (%), 2017
Figure 47: Lenalidomide, Clinical Trials by Trial status (%), 2017
Figure 48: Global Market Size of PTCL in USD Millions (2013-2025)
Figure 49: Market Size of PTCL- 7MM in USD Millions (2013-2025)
Figure 50: Market Size of PTCL Country-wise in USD Millions (2016)
Figure 51: Market Size of PTCL Country-wise in USD Millions (2025)
Figure 52: Market Size of PTCL in United States in USD Millions (2013-2025)
Figure 53: Market Size of PTCL in Germany in USD Millions (2013-2025)
Figure 54: Market Size of PTCL in France in USD Millions (2013-2025)
Figure 55: Market Size of PTCL in United Kingdom in USD Millions (2013-2025)
Figure 56: Market Size of PTCL in Spain in USD Millions (2013-2025)
Figure 57: Market Size of PTCL in Italy in USD Millions (2013-2025)
Figure 58: Market Size of PTCL in Japan in USD Millions (2013-2025)
Figure 1: Classification of Peripheral T- Cell Lymphoma
Figure 2: T-cell neoplasms: organ of origin or involvement and associated chromosomal and genetic alterations.
Figure 3: Incident Cases of PTCL in United States (2013-2025)
Figure 4: Stage wise PTCL cases in United States (2013-2025)
Figure 5: Common types of PTCL in United States (2013-2025)
Figure 6: Incident Cases of PTCL in Germany (2013-2025)
Figure 7: Stage wise PTCL cases in Germany (2013-2025)
Figure 8: Common types of PTCL in Germany (2013-2025)
Figure 9: Incident Cases of PTCL in Italy (2013-2025)
Figure 10: Stage wise PTCL cases in Italy (2013-2025)
Figure 11: Common types of PTCL in Italy (2013-2025)
Figure 12: Incident Cases of PTCL in Spain (2013-2025)
Figure 13: Stage wise PTCL cases in Spain (2013-2025)
Figure 14: Common types of PTCL in Spain (2013-2025)
Figure 15: Incident Cases of PTCL in France (2013-2025)
Figure 16: Stage wise PTCL cases in France (2013-2025)
Figure 17: Common types of PTCL in France (2013-2025)
Figure 18: Incident Cases of PTCL in United Kingdom (2013-2025)
Figure 19: Stage wise PTCL in United Kingdom (2013-2025)
Figure 20: Common types of PTCL in United Kingdom (2013-2025)
Figure 21: Incident Cases of PTCL in Japan (2013-2025)
Figure 22: Stage wise PTCL cases in Japan (2013-2025)
Figure 23: Common Types of PTCL in Japan (2013-2025)
Figure 24: First Line of therapy for PTCL -NOS
Figure 25: Second Line of therapy for PTCL –NOS with Stem cell transplant
Figure 26: First Line of therapy for ALCL, ALK+
Figure 27: Second Line of therapy for ALCL- ALK+ with Stem cell transplant
Figure 28: First Line of therapy for ALCL, ALK-
Figure 29: Second Line of therapy for ALCL- ALK- with Stem cell transplant
Figure 30: First Line of therapy for AICL
Figure 31: Second Line of therapy for AICL with Stem cell transplant
Figure 32: First Line of therapy for Enteropathy associated TCL
Figure 33: Second Line of therapy for enetropathy associated T cell lymphoma with stem cell transplantation
Figure 34: Treatment for Nodal and Extranodal Peripheral T cell Lymphomas
Figure 35: Treatment for relapsed/ refractory Nodal and Extranodal Peripheral T cell Lymphomas
Figure 36: Brentuximab vedotin, Clinical Trials by Zone (%), 2017
Figure 37: Brentuximab Vedotin, Clinical Trials by Trial status (%), 2017
Figure 38: Masitinib, Clinical Trials by Zone (%), 2017
Figure 39: Masatinib, Clinical Trials by Trial status (%), 2017
Figure 40: Darinaparsin, Clinical Trials by Zone (%), 2017
Figure 41: Darinaparsin, Clinical Trials by Trial status (%), 2017
Figure 42: Fenretinide, Clinical Trials by Zone (%), 2017
Figure 43: Fenretinide, Clinical Trials by Trial status (%), 2017
Figure 44: Denileukin diftitox, Clinical Trials by Zone (%), 2017
Figure 45: Denileukin diftitox, Clinical Trials by Trial status (%), 2017
Figure 46: Lenalidomide, Clinical Trials by Zone (%), 2017
Figure 47: Lenalidomide, Clinical Trials by Trial status (%), 2017
Figure 48: Global Market Size of PTCL in USD Millions (2013-2025)
Figure 49: Market Size of PTCL- 7MM in USD Millions (2013-2025)
Figure 50: Market Size of PTCL Country-wise in USD Millions (2016)
Figure 51: Market Size of PTCL Country-wise in USD Millions (2025)
Figure 52: Market Size of PTCL in United States in USD Millions (2013-2025)
Figure 53: Market Size of PTCL in Germany in USD Millions (2013-2025)
Figure 54: Market Size of PTCL in France in USD Millions (2013-2025)
Figure 55: Market Size of PTCL in United Kingdom in USD Millions (2013-2025)
Figure 56: Market Size of PTCL in Spain in USD Millions (2013-2025)
Figure 57: Market Size of PTCL in Italy in USD Millions (2013-2025)
Figure 58: Market Size of PTCL in Japan in USD Millions (2013-2025)
